A 24-hour continuous subcutaneous infusion of foslevodopa/foscarbidopa improved Parkinson’s disease (PD) motor symptoms during all waking hours for patients with advanced disease, according to a new study.
As PD progresses and dosing of oral levodopa/carbidopa (LD/CD) increases, its therapeutic window narrows, resulting in troublesome dyskinesia at peak drug levels and tremors and rigidity when levels fall.
“Foslevodopa/foscarbidopa shows lower OFF time than oral levodopa/carbidopa, and this was statistically significant. Also, foslevodopa/foscarbidopa (fosL/fosC) showed more ON time without dyskinesia compared to oral levodopa/carbidopa. This was also statistically significant,” lead author Sven Stodtmann, PhD, of AbbVie GmbH & Company KG, Ludwigshafen, Germany, reported in his recorded presentation at the Movement Disorders Society’s 23rd International Congress of Parkinson’s Disease and Movement Disorder (Virtual) 2020.
The analysis included 20 patients, and all data from these individuals were collected between 4:30 AM and 9:30 PM.
Participants were 12 men and 8 women, aged 30 to 80 years, with advanced, idiopathic PD responsive to levodopa but inadequately controlled on their current stable therapy, having a minimum of 2.5 OFF hours/day. Mean age was 61.3 ± 10.5 years (range 35-77 years).
In this single arm, open-label study, they received subcutaneous infusions of personalized therapeutic doses of fosL/fosC 24 hours/day for 28 days after a 10- to 30-day screening period during which they recorded LD/CD doses in a diary and had motor symptoms monitored using a wearable device.
Following the screening period, fosL/fosC doses were titrated over up to 5 days, with subsequent weekly study visits, for a total time on fosL/fosC of 28 days. Drug titration was aimed at maximizing functional ON time and minimizing the number of OFF episodes while minimizing troublesome dyskinesia.
Continuous infusion of fosL/fosC performed better than oral LD/CD on all counts.
“The OFF time is much lower in the morning for people on foslevodopa/foscarbidopa [compared with oral LD/CD] because this is a 24-hour infusion product,” Stodtmann explained.
The effect was maintained over the course of the day with little fluctuation with fosL/fosC, OFF periods never exceeding about 25% between 4:30 AM and 9 PM. For LD/CD, OFF periods were highest in the early morning and peaked at about 50% on a 3- to 4-hour cycle during the course of the day.
Increased ON time without dyskinesia varied between about 60% and 80% during the day with fosL/fosC, showing the greatest difference between fosL/fosC and oral LD/CD in the early morning hours.
“ON time with nontroublesome dyskinesia was lower for foscarbidopa/foslevodopa compared to oral levodopa/carbidopa, but this was not statistically significant,” Stodtmann said. ON time with troublesome dyskinesia followed the same pattern, again, not statistically significant.
Looking at the data another way, the investigators calculated the odds ratios of motor symptoms using fosL/fosC compared with oral LD/CD. Use of fosL/fosC was associated with a 59% lower risk of being in the OFF state during the day compared with oral LD/CD (odds ratio [OR], 0.4; 95% CI, 0.2 – 0.7; P < .01).
Similarly, the probability of being in the ON state without dyskinesia was much greater with fosL/fosC (OR, 2.75; 95% CI, 1.08 – 6.99; P < .05).
Indu Subramanian, MD, clinical professor of neurology at the University of California, Los Angeles and director of the Parkinson’s Disease Research, Education and Clinical Center at the West Los Angeles Veterans Affairs Hospital, commented to Medscape Medical News that the field has been waiting to see data on fosL/fosC.
“It seems like it’s pretty reasonable in terms of what the goals were, which is to improve stability of Parkinson’s symptoms, to improve OFF time and give ON time without troublesome dyskinesia,” she said. “So I think those [goals] have been met.”
Subramanian, who was not involved with the research, said she would have liked to have seen results concerning safety of this drug formulation, which the presentation lacked, “because historically, there have been issues with nodule formation and skin breakdown, things like that, due to the stability of the product in the subcutaneous form…So, always to my understanding, there has been this search for things that are tolerated in the subcutaneous delivery.”
If this formulation proves safe and tolerable, Subramanian sees a potential place for it for some patients with advanced PD.
“Certainly a subcutaneous formulation will be better than something that requires… deep brain surgery or even a pump insertion like Duopa [carbidopa/levodopa enteral suspension, AbbVie] or something like that,” she said. “I think [it] would be beneficial over something with the gut because the gut historically has been a problem to rely on in advanced Parkinson’s patients due to slower transit times, and the gut itself is affected with Parkinson’s disease.”
Stodtmann and all coauthors are employees of AbbVie, which was the sponsor of the study and was responsible for all aspects of it. Subramanian has given talks for Acadia Pharmaceuticals and Acorda Therapeutics in the past.
23rd International Congress of Parkinson’s Disease and Movement Disorders (Virtual) 2020: Abstract LBA10. Presented September 12, 2020.